<DOC>
	<DOCNO>NCT02268825</DOCNO>
	<brief_summary>This Phase I dose escalation trial ass MTD MK-3475 combination mFOLFOX6 follow Phase II expansion open label , nonrandomized trial MK-3475 MTD combination mFOLFOX6 supplemental celecoxib 4 cohort advanced/metastatic GI malignancy ( pancreatic , gastro esophageal , colorectal/appendiceal adenocarcinoma biliary carcinoma ) ass response rate , clinical benefit rate , progression free survival overall survival . The Phase II expansion cohort ass effect addition celecoxib patient respond combination MK-3475/mFOLFOX treatment .</brief_summary>
	<brief_title>Phase I/IIA Study MK-3475 With Chemotherapy Patients With Advanced GI Cancers</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Phase I : Patients locally advance metastatic gastrointestinal malignancy mFOLFOX6 indicate treatment Phase IIA expansion : Patients one follow locally advance unresectable metastatic pathologically confirm diagnosis : Colorectal Carcinoma Appendiceal Adenocarcinoma , GastroEsophageal Carcinoma Note : esophageal squamous cell carcinoma exclusionary , Biliary Tract Carcinoma Note : Hepatocellular carcinoma exclude , Pancreatic Carcinoma Patients must willing provide available formalin fix paraffin embed tissue sample archival tissue newly obtain core excisional biopsy tumor lesion central analysis . Note : Fine Needle Aspiration 's ( FNA ) , frozen sample , plastic embed sample , cell block , clot , bone , bone marrow , cytologic specimen exclusionary Patients must measurable disease base irRECIST ( Phase IIA expansion ) Patients must 18 year age day sign inform consent Have performance status 0 1 ECOG Performance Scale Patients must demonstrate adequate organ function base screen lab perform within 14 day treatment initiation Patients allow received prior treatment mFOLFOX6 . If patient currently receive treatment mFOLFOX6 , subject must document disease progression . Patients must also able tolerate standard mFOLFOX6 . Reduced dose mFOLFOX6 enrollment exclusionary . Patients must able provide inform consent willing sign approve consent form conform federal institutional guideline Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Subjects childbearing potential surgically sterilize free menses great 1 year Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Note : Dexamethasone prior treatment day 1 treatment cycle allow Subjects great equal Grade 2 neuropathy Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , great equal Grade 1 baseline ) adverse event due agent administer 4 week earlier Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , less equal Grade 1 baseline ) adverse event due previously administer agent . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy History great equal grade 3 allergic reaction mFOLFOX6 ( patient successfully desensitize oxaliplatin eligible willing undergo desensitization first two cycle mFOLFOX6 per institutional guideline ) Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator , topical steroid local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study Has history interstitial lung disease active , noninfectious pneumonitis require steroid . Has active infection require systemic therapy Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator Has know psychiatric substance abuse disorder would interfere cooperation requirement trial Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Note : testing required baseline unless clinically indicate Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Note : testing required baseline unless clinically indicate Has receive live vaccine within 30 day prior first dose trial treatment Patients ineligible plan regular use NSAIDs dose 2 time per week ( average ) aspirin 325 mg least three time per week , average . Lowdose aspirin exceed 100mg/day permitted . Patients agree stop regular NSAIDS high dose aspirin eligible wash period require . The patient significant bleeding disorder vasculitis . History significant ( opinion investigator ) upper gastrointestinal ulceration , upper gastrointestinal bleeding , upper gastrointestinal perforation within past 3 year . Patients history ulceration , bleed perforation low bowel exclude . Prior allergic reaction hypersensitivity sulfonamide ( may allow per investigator discretion base patient history ) , celecoxib NSAIDs . Cardiac risk factor include : 1 ) Uncontrolled high blood pressure ( systolic blood pressure great 150 ) ; 2 ) Unstable angina ; 3 ) History document myocardial infarction cerebrovascular accident ; 4 New York Heart Association class III IV heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>